Clinical trials
Clinical High Risk clinical trials
Below are recruiting clinical high risk clinical trials, each written for real people, not researchers. We’re tracking 555 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07238998Recruiting
App to help high-risk drinkers reduce alcohol use
This study tests a mobile app that uses motivational interviewing to help high-risk drinkers reduce their alcohol consumption. You may be eligible if you want to cut back on drinking and use an Android phone.
Seoul, SeoulAges 19–59 - NCT06542640Recruiting
Understanding brain changes in youth at risk for psychosis
This research study looks at how the brain changes in young people who are at high risk for developing psychosis. It aims to find better ways to predict and prevent psychosis by using brain imaging and thinking tests.
Shanghai, Shanghai MunicipalityAges 15–35 - NCT06649552Recruiting
French validation of a psychosis risk questionnaire for teens
This study is testing a new French version of a questionnaire (SPI-CY) that helps doctors better understand early signs of psychosis in teenagers. If you are 12 to 17 and already being checked for these signs, you may be able to help improve the tool.
LilleAges 12–17 - NCT06774417Recruiting
Digital strategies to help young people seek help for mental health
This trial tests a digital tool designed to help young people recognize early signs of mental health conditions and take steps toward getting help. It may be a good fit if you are between 12 and 29, live near certain research sites, and can complete a short screening questionnaire in English.
New York, New YorkAges 12–29 - NCT06774430Recruiting
Digital outreach for young people at risk of psychosis
This study tests a digital program designed to encourage young people to seek help for early signs of psychosis. It aims to see if online messages can increase connections to care.
New York, New YorkAges 12–29 - NCT06947083RecruitingPhase 2
Elranatamab after cilta-cel for high-risk multiple myeloma
This trial tests a new drug, elranatamab, for people with multiple myeloma who recently received a CAR-T cell therapy (cilta-cel) but still have high-risk features. The goal is to see if elranatamab can help keep the cancer from coming back.
Tampa, FloridaAges 18 years+ - NCT07499934Recruiting
Mindfulness experience for young people at risk of psychosis
This study explores how young people who are at high risk for psychosis or have had a first episode experience mindfulness. It uses interviews to understand their personal experience, which could help improve future treatments.
LaxouAges 15–30 - NCT03970005Enrolling by invitation
Step-based program for teens with early signs of psychosis
This trial tests a staged (“step-based”) mental health program for people ages 12–25 who have early warning signs that could develop into psychosis. It may help by targeting symptoms early and reducing the chance of worsening over time.
Columbus, OhioAges 12–25 - NCT07187908RecruitingPhase 2
Study of Efbemalenograstim Alfa to prevent low white blood cell counts in cancer patients
This trial tests if a drug called Efbemalenograstim Alfa can help prevent a serious drop in white blood cells (febrile neutropenia) during chemotherapy. It is for patients with solid tumors who have a high or intermediate risk of this condition.
Zhengzhou, HenanAges 18–75 - NCT07450599RecruitingPhase 2
Darolutamide plus hormone therapy before prostate cancer surgery
This trial tests a medicine called darolutamide taken with hormone therapy (ADT) before surgery to remove the prostate. It is for men with a high-risk prostate cancer that has not spread to other parts of the body.
Hefei, AnhuiAges 18 years+ - NCT07237230Recruiting
Gamma-delta T cells to prevent leukemia relapse after transplant
This trial tests if a special type of immune cell called gamma-delta T cells can help prevent acute myeloid leukemia from coming back after a stem cell transplant. It is for people with high-risk features who have recently had a transplant.
Wuhan, HubeiAges 18–65 - NCT06623110RecruitingPhase 2
RP2 vaccine to prevent mouth cancer in high-risk pre-cancer
This trial tests an injected virus therapy (RP2) to stop pre-cancerous mouth lesions from turning into cancer. It is for people with high-risk oral pre-cancer or a history of early-stage head and neck cancer with certain worrisome features.
Boston, MassachusettsAges 18 years+ - NCT07416682RecruitingEarly Phase 1
CAR-T cell therapy for high-risk plasma cell cancers
This trial tests a new immune cell therapy (CAR-T) that targets two markers on high-risk plasma cell cancers. It aims to see if this treatment is safe and helpful for people with aggressive or resistant forms of this disease.
Beijing, Beijing MunicipalityAges 18–75 - NCT07053618Recruiting
Heart pump support for high-risk heart procedures
This trial tests a temporary heart pump to support patients with weak hearts (ejection fraction 35% or less) who need a high-risk stent procedure instead of bypass surgery. The pump may help keep blood flowing during the procedure.
Beijing, Beijing MunicipalityAges 18–90 - NCT07242352RecruitingPhase 3
Comparing elacestrant to standard hormone therapy for high-risk early breast cancer
This trial tests a new hormone therapy drug called elacestrant against standard hormone treatments for people with a specific type of early breast cancer (ER+/HER2-) that has a high chance of coming back. The goal is to see if elacestrant works better at keeping the cancer from returning.
Mannheim, Baden-WurttembergAges 18 years+ - NCT06802952Recruiting
Personalized magnetic brain stimulation for early psychosis risk
This study tests whether a type of magnetic brain stimulation (rTMS) can help people who are at high risk for psychosis. The stimulation is personalized using a brain scan called magnetoencephalography (MEG) to target the right areas.
ShanghaiAges 13–35 - NCT07093671Recruiting
Therapy for Teens and Young Adults at Risk for Psychosis
This trial tests a type of therapy called Mentalization Based Treatment (MBT) for young people who are at high risk for developing psychosis. The therapy helps you understand your own and others' thoughts and feelings, with the goal of reducing distress and preventing psychosis.
LausanneAges 14–30 - NCT03775954Recruiting
Fetal heart testing in high-risk pregnancies after baby loss
This study checks unborn babies’ heart signals using special scans during pregnancy and then checks the baby’s heart shortly after birth. It may help researchers understand why certain high-risk pregnancies can lead to fetal demise and improve care.
Madison, WisconsinAges 18 years+ - NCT06277050RecruitingPhase 3
Toripalimab and capecitabine after chemo-radiation for high-risk nasopharyngeal cancer
This trial tests whether adding the immunotherapy drug toripalimab to the chemotherapy pill capecitabine after standard treatment helps prevent nasopharyngeal cancer from coming back. It is for people with high-risk features who have already had chemo and radiation.
Ganzhou, JiangxiAges 18–70 - NCT07027124RecruitingPhase 2
High-risk prostate cancer treatment before and after surgery
This trial tests a combination of hormone therapy, a targeted pill (Darolutamide), and an immunotherapy drug (Pembrolizumab) before and after surgery for men with high-risk prostate cancer that has specific genetic features. The goal is to see if this approach helps prevent the cancer from coming back.
New York, New YorkAges 18 years+ - NCT07549399RecruitingPhase 3
Radiation, Chemotherapy, and Immunotherapy for Rectal Cancer
This trial tests a combination of radiation, chemotherapy, and immunotherapy drugs before surgery for people with locally advanced rectal cancer. The goal is to shrink the tumor and improve outcomes for patients with higher-risk disease.
Guangzhou, GuangdongAges 18–75 - NCT07483970RecruitingPhase 1
JL19001 alone or with BCG for high-risk non-muscle invasive bladder cancer
This trial tests a new drug called JL19001, given alone or with BCG (a standard bladder cancer treatment), for people with high-risk bladder cancer that hasn't spread into the bladder muscle. The goal is to see if it can help prevent the cancer from coming back or getting worse.
Chengdu, SichuanAges 18 years+ - NCT05877573Recruiting
Toripalimab with chemo-radiation before surgery for rectal cancer
This trial studies whether adding toripalimab (an immunotherapy drug) to standard chemo-radiation before surgery can improve outcomes for people with higher-risk, locally advanced rectal cancer. It is meant for cancers that are mismatch-repair “MSS/pMMR,” and it checks safety plus effectiveness as a first treatment.
Guangzhou, GuangdongAges 18–75 - NCT07054346RecruitingPhase 1
Comparing two radiation drugs for high-risk prostate cancer before surgery
This trial tests two radioactive drugs (Lu-177 and Ac-225 PSMA-617) given before prostate removal surgery in men with high-risk prostate cancer that hasn't spread far. The goal is to see which drug works better at targeting cancer cells.
San Francisco, CaliforniaAges 18 years+
Hear when a new Clinical High Risk trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for clinical high risk?
- Yes. Clin2 currently lists 555 recruiting clinical high risk studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a clinical high risk trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a clinical high risk trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.